|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-11-20 EST
|
5-day change | 1st Jan Change | ||
| 0.0892 SEK | -3.67% |
|
-4.09% | -70.27% |
Company Valuation: Prostatype Genomics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 188.6 | 134.9 | 48.46 | 11.35 | 74.42 | 17.76 |
| Change | - | -28.46% | -64.07% | -76.58% | 555.78% | -76.14% |
| Enterprise Value (EV) 1 | 174.2 | 115.8 | 37.84 | 20.33 | 65.07 | 13.99 |
| Change | - | -33.5% | -67.33% | -46.26% | 220.01% | -78.5% |
| P/E | - | -8.09x | -1.38x | -0.19x | -0.38x | -0.23x |
| PBR | 6.67x | 3.76x | 1.85x | 0.46x | 2.22x | 0.67x |
| PEG | - | - | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | 146x | 13,487x | 71x | 8.37x | 374x | 29.9x |
| EV / Revenue | 135x | 11,581x | 55.4x | 15x | 327x | 23.6x |
| EV / EBITDA | -14.3x | -7.49x | -1.32x | -0.52x | -1.6x | -0.38x |
| EV / EBIT | -14.2x | -7.45x | -1.32x | -0.52x | -1.59x | -0.36x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | -1,106 | -1,533 | -512.7 | -29.1 | -1.317 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 1.293 | 0.01 | 0.6828 | 1.356 | 0.199 | 0.594 |
| EBITDA 1 | -12.15 | -15.46 | -28.64 | -39.23 | -40.73 | -36.75 |
| EBIT 1 | -12.25 | -15.55 | -28.69 | -39.25 | -40.85 | -38.94 |
| Net income 1 | -13.69 | -15.63 | -29.09 | -41.44 | -41.05 | -44.5 |
| Net Debt 1 | -14.4 | -19.06 | -10.62 | 8.985 | -9.353 | -3.768 |
| Reference price 2 | 14,300.0000 | 8,940.0000 | 2,120.0000 | 95.0000 | 11.1000 | 0.3000 |
| Nbr of stocks (in thousands) | 13.2 | 15.1 | 22.9 | 119 | 6,705 | 59,189 |
| Announcement Date | 5/16/21 | 5/4/22 | 5/3/23 | 4/24/24 | 4/23/25 | 5/31/26 |
1SEK in Million2SEK
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 6.28M | ||
| 11.42x | 0.37x | 7.54x | 3.31% | 102B | ||
| 15.21x | 1.86x | 9.27x | 0.68% | 96.16B | ||
| -183.2x | 13.6x | -208.13x | -.--% | 42.04B | ||
| 16.17x | 1.67x | 10.07x | 2.29% | 32.01B | ||
| 27.14x | 2.37x | 13.44x | 0.79% | 29.95B | ||
| 25.1x | 2.77x | 14.07x | 1.28% | 28.5B | ||
| 7.25x | 1.43x | 6.24x | -.--% | 20.98B | ||
| 28.68x | 5.14x | 21.05x | 2.44% | 19.4B | ||
| 30.57x | 2.87x | 12.92x | 1.45% | 16.97B | ||
| Average | -2.41x | 3.56x | -12.61x | 1.36% | 39B | |
| Weighted average by Cap. | -4.63x | 3.01x | -13.39x | 1.57% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PROGEN Stock
- Valuation Prostatype Genomics AB
Select your edition
All financial news and data tailored to specific country editions
















